NCT04060108已完成不适用
Mapping the Influence of Drugs of Abuse on Risk and Reward Circuits - MDMA
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Facial Expressions of Emotion Task (FEET, nonconscious and conscious) evoked functional activity and connectivity
研究概览
简要总结
This study is a biomarker study designed to characterize how human neural circuits and behaviors are modified during altered states induced by MDMA.
详细描述
The investigators will assess the effect of acute MDMA modulation on the functioning of human brain circuits. Brain circuits will be assessed using functional magnetic resonance imaging.
Participants will include volunteers who report more than two prior uses of MDMA (also known as Ecstasy), when they were 18 years or older.
The investigators will recruit individuals who have previously tried MDMA rather than those who are MDMA-naïve.
Participants will receive an oral dose of MDMA (80mg and 120mg) and placebo (saline) at 3 separate study sessions. Following established procedures, these three sessions will be randomized in a blinded protocol in order to limit expectancy effects.
Throughout each session, participants will be monitored. Functional imaging will commence after the drug has reached peak levels, following previously established time courses for MDMA administered orally. Participants will also be monitored after the functional imaging session. Secondary effects of MDMA on behavior and self-reported experience will be assessed.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Crossover
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able to swallow capsules
- •All genders and ethno-racial categories
- •Able and willing to enroll and provide written informed consent.
- •Able to comply with study procedures.
- •2+ prior uses of MDMA when aged 18 years or older and have reported no serious adverse reactions from MDMA or ecstasy.
- •Non-nicotine user, defined as no primary nicotine exposure for last six months.
- •Agree to not use caffeine for 12 hours before and 10 hours after drug administration.
- •Not using any medication or substance that might increase the risk of participation and/or interact with MDMA (i.e., serotonergic agents, antidepressants, opiates, any drugs with known interactions with Monoamine Oxidase Inhibitors).
- •Must agree to inform the investigators within 48 hours of any changes in medical conditions or procedures.
- •If of childbearing potential, must have a negative pregnancy test at study entry and prior to each drug session and must agree to use adequate birth control through 10 days after the last drug session. Adequate birth control methods include intrauterine device (IUD), injected or implanted hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones.
- •Able to receive an MRI.
排除标准
- •Have current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator.
- •Current psychiatric, mood, anxiety, eating or psychotic disorder assessed at screening with the MINI and medical history.
- •Current use of any psychotropic medication (a wash-out period of 5 half-lives will be required prior to drug visits followed by a 1-week stabilization period, if the participant reports recently discontinuing a psychotropic medication).
- •Have used Ecstasy (material represented as containing MDMA) within 6 months of the first study dose; or have previously participated in a MAPS-sponsored MDMA clinical trial.
- •Positive for drug, or alcohol abuse disorders as assessed through DAST, CUDIT-R, Fagerstrom and AUDIT measures.
- •Positive test on urine drug screen for illicit and/or drugs of abuse at screening and prior to study drug administration.
- •Concurrent use of any medication or substance that might increase the risk of participation and/or interact with MDMA (i.e., serotonergic agents, antidepressants, opiates, any drugs with known interactions with Monoamine Oxidase Inhibitors).
- •Unable or unwilling to agree to refrain from using any psychoactive substances (i.e., cannabis), supplements (i.e., St. John's Wort, SAMe, 5HTP) and nonprescription medications (i.e., dextromethorphan) starting 1-week prior to study start and for duration of study.
- •Current use of any opioids, including codeine, hydrocodone, and morphine.
- •Have an exclusionary metal device (e.g., presence of metallic device or dental braces, which are contraindications for MRI) as determined by the discretion of the Clinical Investigator.
- •BMI outside of healthy range (18-30)
- •Inability to speak, read or understand English at a 5th grade level or severe hearing impairment.
- •Plan to move out of the area during the study period (given repeated testing sessions)
- •Individuals who are pregnant or nursing.
- •Schizophrenia in a first degree relative.
- •Direct physical access to or routinely handling of addicting drugs in the regular course of work duties.
- •Allergy or hypersensitivity to MDMA
- •Renal/hepatic impairment (assessed via laboratory tests during initial screening appointment)
- •Hypertension (Hypertension, Stage 1 as defined by a systolic blood pressure >140 mmHg or diastolic blood pressure > 90 mmHg on two of three measurements at least 15 minutes apart at initial screening appointment; systolic blood pressure >155 mmHg or diastolic blood pressure >99 mmHg on two of three measurements at least 15 minutes apart during drug administration visits)
- •Heart rate <50bpm or >150bpm assessed at initial screening visit (PI discretion for bradycardia)
- •Chronic congestive heart failure, tachyarrhythmias, myocardial ischemia (assessed via EKG at initial screening appointment)
- •Have a marked Baseline prolongation of QT/QTc interval e.g., repeated demonstration of a QTc interval >450 milliseconds (ms) in males and >460 ms in females. For transgender or non-binary participants, QTc interval will be evaluated based on sex assigned at birth, unless the participant has been on hormonal treatment for 5 or more years.
- •Have evidence or history of significant (controlled or uncontrolled) hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of MDMA administration (participants with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded). Note: if participants present with a history of glaucoma, enrollment would be allowed only with the approval of their ophthalmologist.
- •Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- •Have history of hyponatremia or hyperthermia
研究组 & 干预措施
MDMA Within Subject Cross-over
Participants will be randomized to high-dose, low-dose, or placebo for each of the the three study sessions.
干预措施: MDMA (Drug)
结局指标
主要结局
Facial Expressions of Emotion Task (FEET, nonconscious and conscious) evoked functional activity and connectivity
时间窗: up to 2 hours after the administration of MDMA or Placebo
For the non-conscious task, participants are shown a series of faces, presented in pairs. The first face in each pair is presented for only a fraction of a second and may be hard to see. Participants press a button every time they see a face. For the conscious task, participants do the same thing same but with a new set of faces.
次要结局
- Resting-state functional activity and connectivity(up to 2 hours after the administration of MDMA or Placebo)
- MID evoked functional activity and connectivity(up to 2 hours after the administration of MDMA or Placebo)
- Go-No-Go evoked functional activity and connectivity(up to 2 hours after the administration of MDMA or Placebo)
- Behavioral responses on the WebNeuro computerized test battery assessing cognitive capacity(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 21-item Depression, Anxiety and Stress Scale (DASS)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 29-item Rotter's Locus of Control (RLoC)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 15-item Mini Brief Risk-Resilience Index for Screening (BRISC)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 14-item Snaith-Hamilton Please Scale (SHAPS)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 24-item Dimensional Apathy Scale (DAS)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 18-item Motivation and Pleasure Scale Self-Report (MAP-SR)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 17-item Dimensional Anhedonia Rating Scale (DARS)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 94-item 5-Dimensional Altered States of Consciousness Rating Scale (DASC)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 23-item Social Reward Questionnaire (SRQ)(up to 5 hours after the administration of MDMA or Placebo)
- Self-administered computerized task assessed by Multifaceted Empathy Test (MET)(up to 5 hours after the administration of MDMA or Placebo)
- Level of subjectively experienced mood and feelings as assessed by rating scale(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the 23-item Clinician Administered Dissociative States Scale (CADSS)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by a clinician on the 18-item Brief Psychiatric Rating Scale (BPRS)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the MID Cue Rating(up to 5 hours after the administration of MDMA or Placebo)
- Self-reported responses as assessed by the Face Likability Rating(up to 5 hours after the administration of MDMA or Placebo)
- Steroid hormone assay via saliva collection(up to 5 hours after the administration of MDMA or Placebo)
- Qualitative free responses(up to 5 hours after the administration of MDMA or Placebo)
研究者
Leanne Williams
Professor of Psychiatry and Behavioral Sciences
Stanford University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Stanford Regulating Circuits of the Brain Study- KetamineHealthyNCT03475277Stanford University13
已完成
1 期
Neurological Influences on Drug Prevention InterventionYouths At-risk for Drug Use/AbuseNCT00198939University of Florida330
已完成
不适用
Cognitive Task Development and Implementation for Functional MRI StudiesDrug AbuseNicotine DependenceNCT01036685National Institute on Drug Abuse (NIDA)525
已完成
1 期
A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy SubjectsHealthy VolunteerNCT01365338Biogen112
招募中
2 期
Opioid/Benzodiazepine Polydrug Abuse: Aim 3Opioid AbuseBenzodiazepine AbusePolysubstance AbuseNCT05006079Wayne State University24